These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25917093)

  • 1. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
    Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
    J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome.
    Nozal P; Bernabéu-Herrero ME; Uzonyi B; Szilágyi Á; Hyvärinen S; Prohászka Z; Jokiranta TS; Sánchez-Corral P; López-Trascasa M; Józsi M
    Mol Immunol; 2016 Feb; 70():47-55. PubMed ID: 26703217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
    Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
    Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
    Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
    Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
    Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
    Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.
    Valoti E; Alberti M; Iatropoulos P; Piras R; Mele C; Breno M; Cremaschi A; Bresin E; Donadelli R; Alizzi S; Amoroso A; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2019; 10():853. PubMed ID: 31118930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.
    Blanc C; Roumenina LT; Ashraf Y; Hyvärinen S; Sethi SK; Ranchin B; Niaudet P; Loirat C; Gulati A; Bagga A; Fridman WH; Sautès-Fridman C; Jokiranta TS; Frémeaux-Bacchi V; Dragon-Durey MA
    J Immunol; 2012 Oct; 189(7):3528-37. PubMed ID: 22922817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor H Autoantibodies and Complement-Mediated Diseases.
    Zhang Y; Ghiringhelli Borsa N; Shao D; Dopler A; Jones MB; Meyer NC; Pitcher GR; Taylor AO; Nester CM; Schmidt CQ; Smith RJH
    Front Immunol; 2020; 11():607211. PubMed ID: 33384694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.
    Bhattacharjee A; Reuter S; Trojnár E; Kolodziejczyk R; Seeberger H; Hyvärinen S; Uzonyi B; Szilágyi Á; Prohászka Z; Goldman A; Józsi M; Jokiranta TS
    J Biol Chem; 2015 Apr; 290(15):9500-10. PubMed ID: 25659429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
    Moore I; Strain L; Pappworth I; Kavanagh D; Barlow PN; Herbert AP; Schmidt CQ; Staniforth SJ; Holmes LV; Ward R; Morgan L; Goodship TH; Marchbank KJ
    Blood; 2010 Jan; 115(2):379-87. PubMed ID: 19861685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.
    Foltyn Zadura A; Zipfel PF; Bokarewa MI; Sturfelt G; Jönsen A; Nilsson SC; Hillarp A; Saxne T; Trouw LA; Blom AM
    Arthritis Res Ther; 2012 Aug; 14(4):R185. PubMed ID: 22894814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
    Dragon-Durey MA; Blanc C; Marliot F; Loirat C; Blouin J; Sautes-Fridman C; Fridman WH; Frémeaux-Bacchi V
    J Med Genet; 2009 Jul; 46(7):447-50. PubMed ID: 19435718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder.
    Uzonyi B; Szabó Z; Trojnár E; Hyvärinen S; Uray K; Nielsen HH; Erdei A; Jokiranta TS; Prohászka Z; Illes Z; Józsi M
    Front Immunol; 2021; 12():660382. PubMed ID: 33986750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-complement-factor H-associated glomerulopathies.
    Durey MA; Sinha A; Togarsimalemath SK; Bagga A
    Nat Rev Nephrol; 2016 Sep; 12(9):563-78. PubMed ID: 27452363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
    Grenda R; Jarmużek W; Rubik J; Prokurat S; Miklaszewska M; Drozdz D; Zachwieja K; Ardissino G; Hofer J
    Pediatr Transplant; 2015 Sep; 19(6):E130-4. PubMed ID: 26087050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
    Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele
    Pouw RB; Gómez Delgado I; López Lera A; Rodríguez de Córdoba S; Wouters D; Kuijpers TW; Sánchez-Corral P
    Front Immunol; 2018; 9():848. PubMed ID: 29740447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome.
    Cugno M; Berra S; Depetri F; Tedeschi S; Griffini S; Grovetti E; Caccia S; Cresseri D; Messa P; Testa S; Giglio F; Peyvandi F; Ardissino G
    J Am Soc Nephrol; 2021 May; 32(5):1227-1235. PubMed ID: 33712527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The autoimmune disease DEAP-hemolytic uremic syndrome.
    Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
    Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.